Overview

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation at various doses in patients with diabetic macular edema.
Phase:
Phase 2
Details
Lead Sponsor:
Santen Inc.
Collaborator:
MacuSight, Inc.
Treatments:
Everolimus
Sirolimus